Tier 2 — strong

Management of aphthous ulceration with topical quercetin: a randomized clinical trial

Ahmed Abd El-Meguid Mostafa Hamdy, Mohamed Abd El-Moneam Ibrahem
The journal of contemporary dental practice 2010 11(4):E009

Bibliography

PubMed
PMID 20953559
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignRandomized active-comparator topical mouth-ulcer trial
ModelHuman intervention research
Sample40 men with minor aphthous ulcers
InterventionTopical quercetin three times daily versus benzydamine mouthwash
DurationUp to 10 days
EndpointsSource-specific outcomes described in the key findings

What the study showed, in plain terms

Published in 2010, this source examined skin and topical formulations. Design: Randomized active-comparator topical mouth-ulcer trial. Sample/model: 40 men with minor aphthous ulcers. The exposure or intervention was Topical quercetin three times daily versus benzydamine mouthwash. Follow-up or treatment period: Up to 10 days.

Ulcer size and healing outcomes favored topical quercetin in the reported comparisons.

Small male-only study without a placebo cream; spontaneous healing and differences in treatment format complicate interpretation. It does not test oral quercetin capsules.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Skin and Hair: Oral vs Topical Evidence. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Ulcer size and healing outcomes favored topical quercetin in the reported comparisons.
  • The recorded outcome domains were Source-specific outcomes described in the key findings.
  • The result applies to the tested exposure: Topical quercetin three times daily versus benzydamine mouthwash; Up to 10 days.

What this study can and cannot tell us

  • Small male-only study without a placebo cream; spontaneous healing and differences in treatment format complicate interpretation. It does not test oral quercetin capsules.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Soothing and anti-itch effect of quercetin phytosome in human subjects: a single-blind study
Giada Maramaldi et al. · Clinical, cosmetic and investigational dermatology · 2016
Tier 2
Comparative evaluation of the effect of permeation enhancers, lipid nanoparticles and colloidal silica on in vivo human skin penetration of quercetin
S Scalia et al. · Skin pharmacology and physiology · 2013

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology